Cure My Disease

Don't miss your cure!

Log in / Sign up

New clotting factor offers continued bleeding control for hemophilia a patients

NCT ID NCT06716814

Recruiting now Disease control Sponsor: Swedish Orphan Biovitrum Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study gives people with moderate or severe hemophilia A who finished a previous trial continued access to the drug efanesoctocog alfa. The drug is a lab-made clotting factor that helps prevent bleeding episodes. Researchers will monitor safety and how well it controls bleeding until the drug becomes commercially available or until March 2027.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Efanesoctocog alfa (a lab-made clotting factor protein)
What this could lead to: If successful, this study will show that long-term use of efanesoctocog alfa is safe and effective at preventing bleeding episodes in people with hemophilia A.
What could go wrong: This is an open-label roll-over study, not a randomized trial, so results may be less definitive. Side effects or reduced effectiveness over time are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A (MODERATE OR SEVERE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease coagulation protein disease follicular lymphoma hemophilia A moderately severe hemophilia A severe hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAEMOPHILIA A (MODERATE OR SEVERE) SEVERE HAEMOPHILIA A

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Plovdiv, Bulgaria
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Sofia, Bulgaria
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Brest, France
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Bron, France
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Lille, France
Sobi Investigational Site
WITHDRAWN

Strasbourg, France
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Athens, Greece
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Catanzaro, Italy
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Florence, Italy
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Milan, Italy
Sobi Investigational Site
RECRUITING

Naples, Italy
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Parma, Italy
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Rome, Italy
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Rozzano, Italy
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Vicenza, Italy
Sobi Investigational Site
RECRUITING

Oslo, Norway
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

A Coruña, Spain
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Zaragoza, Spain
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Gothenburg, Sweden
Sobi Investigational Site
RECRUITING

Lund, Sweden
Sobi Investigational Site
ACTIVE_NOT_RECRUITING

Stockholm, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.